News
News
Local News
Crime & Public Safety
Your Tax Dollars At Work
Politics
Massachusetts
Nation
World
Business
Health
Weather
Columnists
Traffic
Sports
Sports
Red Sox
Patriots
Celtics
Bruins
College
High School
More Sports
Scores & Stats
Entertainment
Entertainment
Celebrity News
Arts & Culture
Movies
Television
Music
Fun & Games
Horoscope
Lottery
Comics
Puzzles
Lifestyle
Lifestyle
Food & Beverage
Travel
Style & Fashion
Obituaries
Obituaries
Local Obituaries
Submit an Obituary
Opinion
Opinion
Editorials
Op-Ed
Letters
Submit a Letter
Radio
Weather
E-Edition
Subscribe
Sign Up For Newsletters
News
News
Local News
Crime & Public Safety
Your Tax Dollars At Work
Politics
Massachusetts
Nation
World
Business
Health
Weather
Columnists
Traffic
Sports
Sports
Red Sox
Patriots
Celtics
Bruins
College
High School
More Sports
Scores & Stats
Entertainment
Entertainment
Celebrity News
Arts & Culture
Movies
Television
Music
Fun & Games
Horoscope
Lottery
Comics
Puzzles
Lifestyle
Lifestyle
Food & Beverage
Travel
Style & Fashion
Obituaries
Obituaries
Local Obituaries
Submit an Obituary
Opinion
Opinion
Editorials
Op-Ed
Letters
Submit a Letter
Radio
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Immix Biopharma, Inc.
< Previous
1
2
Next >
Immix Biopharma Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2
August 28, 2024
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Tickers
IMMX
Immix Biopharma Doses 1st Patient in U.S. AL Amyloidosis Trial with CAR-T NXC-201
July 08, 2024
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Tickers
IMMX
Immix Biopharma to Present at the Stifel 2024 Cell Therapy Forum
June 17, 2024
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Tickers
IMMX
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma
April 29, 2024
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Tickers
IMMX
Immix Biopharma on Track to Dose NXC-201 Patients in United States
April 18, 2024
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Tickers
IMMX
Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial
March 20, 2024
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Tickers
IMMX
Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiative
March 05, 2024
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Tickers
IMMX
Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock
February 08, 2024
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Tickers
IMMX
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis
February 07, 2024
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Tickers
IMMX
Immix Biopharma Announces Pricing of $15 Million Public Offering of Common Stock
February 05, 2024
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Tickers
IMMX
Immix Biopharma Announces Proposed Public Offering of Common Stock
February 05, 2024
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Tickers
IMMX
Immix Biopharma Statement On January 2024 FDA Labeling Change Notification For Approved CAR-T Products
January 24, 2024
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Tickers
IMMX
Immix Biopharma Announces Dr. Vaishali Sanchorawala, AL Amyloidosis Thought Leader, Director of the Amyloidosis Center at Boston University and Boston Medical Center, Joins Scientific Advisory Board
January 04, 2024
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Tickers
IMMX
Immix Biopharma Announces Dr. Marko Radic, Autoimmune CAR-T Pioneer and Associate Professor at the University of Tennessee Health Science Center, Joins Scientific Advisory Board
December 18, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Tickers
IMMX
Immix Biopharma Announces 100% Overall Response Rate (n=10); 23.7 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2023
December 11, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Tickers
IMMX
Immix Biopharma to Present at the 2023 JMP Securities Hematology and Oncology Summit
November 30, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Tickers
IMMX
Immix Biopharma to Host KOL Event to Discuss its BCMA-Targeted CAR-T Cell Therapy Candidate NXC-201 for Relapsed/Refractory AL Amyloidosis
November 22, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Tickers
IMMX
Immix Biopharma Announces FDA Approval of IND Application for CAR-T NXC-201, Enabling U.S. Patient Dosing
November 21, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Tickers
IMMX
Immix Biopharma Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 9 Relapsed/Refractory AL Amyloidosis Patients
November 06, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Tickers
IMMX
Immix Biopharma Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 63 Relapsed/Refractory Multiple Myeloma Patients
November 06, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Tickers
IMMX
Immix Biopharma Subsidiary Nexcella Announces Dr. Michaela Liedtke, Stanford Medicine Cancer Center Hematology Program Lead and Co-Director Stanford Amyloid Center, Joins Scientific Advisory Board
October 26, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Tickers
IMMX
Immix Biopharma Completes 3rd NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site
October 16, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Tickers
IMMX
Immix Biopharma Announces Complete Response in 9th Relapsed/Refractory AL Amyloidosis Patient in NXC-201 Clinical Trial at IMS 20th Annual Meeting
October 03, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Tickers
IMMX
Immix Biopharma Announces 72-Patient NXC-201 Clinical Data at the IMS 20th Annual Meeting, 95% Overall Response Rate in Multiple Myeloma
October 02, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Tickers
IMMX
U.S. Food and Drug Administration Approves Orphan Drug Designation for Immix Biopharma NXC-201 as a Treatment for Amyloid Light Chain (AL) Amyloidosis
September 21, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Tickers
IMMX
Immix Biopharma Subsidiary Nexcella Completes 2nd NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site
September 19, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Tickers
IMMX
Nexcella, Immix Biopharma Subsidiary, to Present at the Bank of America 2023 Healthcare Trailblazers Private Company Conference
September 07, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Tickers
IMMX
Immix Biopharma Announces Dr. Suzanne Lentzsch, Director of the Multiple Myeloma and Amyloidosis Program at the College of Physicians and Surgeons of Columbia University and at New York Presbyterian Hospital in New York, Joins Scientific Advisory Board
September 01, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Tickers
IMMX
U.S. Food and Drug Administration Approves Orphan Drug Designation for Immix Biopharma NXC-201 as a Treatment for Multiple Myeloma
August 23, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Tickers
IMMX
Immix Biopharma Announces Dr. Heather Landau, Memorial Sloan Kettering Cancer Center Amyloidosis Program Director, Joins Nexcella Scientific Advisory Board
August 18, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Tickers
IMMX
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Close